Changes in the immune cell profile, clinical and safety outcomes in fingolimod-treated patients with relapsing multiple sclerosis: interim results of the FLUENT study
1Autoimmunity Center of Excellence, Multiple Sclerosis Center, University of Michigan, Ann Arbor, MI, USA; 2Mellen Center, Cleveland Clinic, Cleveland, OH, USA; 3Center for Neuroinflammation and Experimental Therapeutics,
and the Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
4UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA; 5Stanford University, Stanford, CA, USA; 6Missouri Baptist Medical Center, St Louis, MO, USA; 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Platform Presentation DXM03 May 31, 2019 Yang Mao-Draayer1, Jeffrey Cohen2, Amit Bar-Or3, Bruce A.C. Cree4, May H. Han5, Barry Singer6, Scott Kolodny7, Xiangyi Meng7, Lesley Schofield7, Marina Ziehn7, on behalf of the FLUENT study investigators
2
Disclosures
Funding source: This study is supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Yang Mao-Draayer has received consulting and/or speaker fees from Biogen, Bayer Pharmaceuticals, Celgene, EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme, and Teva, and research support from Genzyme, NIH NIAID Autoimmune Center of Excellence, Novartis, and Chugai. Jeffrey Cohen has received consulting fees from Adamas and Celgene and research support from Biogen Idec, Roche/Genentech, GSK, Merck/EMD Serono, Medimmune, Novartis, Celgene/Receptos, and Sanofi-Genzyme. Amit Bar-Or has received consulting and/or speaker fees and research support from Biogen Idec, Roche/Genentech, GSK, Merck/EMD Serono, Medimmune, Novartis, Celgene/Receptos, and Sanofi-Genzyme. Bruce A.C. Cree has received consulting fees from AbbVie, Akili, Alexion, Biogen, EMD Serono, GeNeuro, Novartis, Sanofi- Genzyme, and TG Therapeutics. May H. Han has served on advisory boards for Novartis and has received speaker fees from Sanofi-Genzyme, and research support from Accorda, Hoffman La Roche, MedImmune, Novartis, Receptos, and Teva. Barry Singer has received consulting and/or speaker fees from Acorda, Bayer, Biogen, Celgene, EMD Serono, Genentech, Novartis, Sanofi-Genzyme, Teva, and TG Therapeutics, and research support from AbbVie, Acorda, Alkermes, Biogen, MedImmune, Novartis, Roche, and Sanofi-Genzyme. Scott Kolodny, Xiangyi Meng, Lesley Schofield, and Marina Ziehn are employees of Novartis Pharmaceuticals Corporation. Acknowledgments: Medical w riting and editorial support in the development of this poster w ere provided by Catherine Simonson of Indicia Medical, part of the Fishaw ack Group of Companies, Oxford, UK and funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Ryan Winger of Novartis Pharmaceuticals Corporation contributed to the concept and design of the FLUENT study. Chelsea Elam of Novartis Pharmaceuticals Corporation provided data for, and review ed, this presentation.